Synapse - Works

Results (5712)

A phase 1 study of CFT7455, a novel degrader of IKZF1/3, in multiple myeloma and non-Hodgkin lymphoma

Meeting Abstract

Berdeja, J.; Ailawadhi, S.; Horwitz, S. M.; Matous, J. V.; Mehta-Shah, N.; Martin, T.; Muchtar, E.; Richardson, P. G.; Richard, S.; Bhutani, M.; more...
Blood (2021)

Fulltext@MSK | Save

Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed/refractory B-cell non-Hodgkin lymphomas (R/R B-NHL): Initial results from a phase I/II study

Meeting Abstract

Bartlett, N. L.; Giri, P.; Budde, L. E.; Schuster, S. J.; Assouline, S.; Matasar, M. J.; Yoon, S. S.; Canales, M.; Gutierrez, N. C.; Fay, K.; more...
Blood (2021)

Fulltext@MSK | Save

Trial-in-progress: Randomized phase II trial in early relapsing or refractory follicular lymphoma (NCT# 03269669): SWOG S1608

Meeting Abstract

Barr, P. M.; Li, H.; Link, B. K.; Flowers, C. R.; Burack, R.; Schöder, H.; Leblanc, M. L.; Weigert, O.; Herrera, A. F.; Weinstock, D. M.; more...
Blood (2021)

Fulltext@MSK | Save

Rational targets in systemic AL amyloidosis

Meeting Abstract

Bal, S.; Dogan, A.; Hassoun, H.; Mailankody, S.; Giralt, S. A.; Landau, H. J.
Blood (2021)

Fulltext@MSK | Save

Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 car NK cell therapy in relapsed/refractory B-cell lymphoma

Meeting Abstract

Bachanova, V.; Ghobadi, A.; Patel, K.; Park, J. H.; Flinn, I. W.; Shah, P.; Wong, C.; Bickers, C.; Szabo, P.; Wong, L.; more...
Blood (2021)

Fulltext@MSK | Save

Multicenter analysis of treatment and outcomes for patient with TP53 mutated AML in the era of novel therapies; Significant impact of allogeneic stem cell transplantation on survival

Meeting Abstract

Badar, T.; Litzow, M. R.; Shallis, R. M.; Bewersdorf, J. P.; Saliba, A.; sacchi De Camargo Correia, G.; Stahl, M.; Goldberg, A. D.; Atallah, E. L.; Foran, J. M.
Blood (2021)

Fulltext@MSK | Save

Selective STAT3 degraders dissect peripheral T-cell lymphomas vulnerabilities empowering personalized regimens

Meeting Abstract

Astone, G.; Cappelli, L. V.; Chiu, W.; Kayembe, C.; Wang, R.; Yang, B.; Sharma, K.; Dey, J.; Karnik, R.; Brambilla, L.; more...
Blood (2021)

Fulltext@MSK | Save

MAIT and Vδ2 unconventional T cells predict favorable outcome after allogeneic HCT and are supported by a diverse intestinal microbiome

Meeting Abstract

Andrlova, H.; Miltiadous, O.; Dai, A.; Gardner, R.; El Daker, S.; Slingerland, J. B.; Giardina, P. A.; Clurman, A.; Gomes, A. L. C.; Nguyen, C. L.; more...
Blood (2021)

Fulltext@MSK | Save

A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (Trial in progress)

Meeting Abstract

Alencar, A. J.; Roeker, L. E.; Hoffman, M.; Murthy, G. S. G.; Patel, V.; Ku, N. C.; Pauff, J. M.; Eyre, T. A.; Jurczak, W.; Le Gouill, S.
Blood (2021)

Fulltext@MSK | Save

Trial in progress: Asciminib in monotherapy 4 CML (AIM4CML), a phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without or with T315I mutations

Meeting Abstract

Andorsky, D.; Tomassetti, S.; Deutsch, Y. E.; Broun, E. R.; Issa, G. C.; Levy, M. Y.; Deininger, M. W.; Maegawa, R.; Shrestha, A.; Mauro, M. J.
Blood (2021)

Fulltext@MSK | Save